Parathyroid Hormone is Negatively Correlated with Glycated Hemoglobin in Newly Diagnosed Type 2 Diabetic Patients

Table 1

Baseline characteristics of the newly diagnosed T2D patients and the controls.

	Control (n = 145)	T2D (n = 387)
Age (years)	43.87 ± 12.39	45.51 ± 11.59	0.155
Sex, male (n) %	13 (14.8%)	281 (72.6%)	<0.001
Symptomatic (n) %	0 (0%)	216 (55.8%)	<0.001
BMI (kg/m^2)	24.75 ± 3.89	26.86 ± 3.33	<0.001
TC (mmol/L)	4.98 ± 0.97	4.93 ± 0.93	0.572
LDL-C (mmol/L)	3.23 ± 1.19	3.12 ± 0.94	0.260
HDL-C (mmol/L)	1.35 ± 0.34	0.97 ± 0.21	<0.001
TG (mmol/L)	1.19 (0.88, 1.80)	1.76 (1.26, 2.60)	<0.001
FFA (mmol/L)	0.56 ± 0.23	0.53 ± 0.18	0.056
Crea (μmol/L)	53.70 (49.10, 60.30)	59.80 (49.52, 69.45)	0.001
FBG (mmol/L)	5.00 (4.74, 5.32)	7.94 (6.63, 9.81)	<0.001
FINS (μIU/mL)	9.30 (6.35, 14.40)	10.10 (7.00, 13.20)	0.560
HbA1c (%)	5.50 (5.28, 5.40)	10.60 (9.70, 11.60)	<0.001
HOMA-IR	1.65 (0.99, 3.15)	3.49 (2.36, 5.09)	<0.001
HOMA-β	114.94 (66.30, 161.36)	41.88 (28.51, 69.34)	<0.001
Ca (mmol/L)	2.37 ± 0.09	2.31 ± 0.10	<0.001
P (mmol/L)	1.23 ± 0.15	1.32 ± 0.20	<0.001
25-OH-D3 (ng/mL)	17.40 (11.81, 23.71)	14.64 (10.93, 19.12)	0.007
PTH (pg/mL)	47.15 (35.83, 58.65)	35.10 (25.90, 47.20)	<0.001

Data are shown as the means ± S.D. unless indicated otherwise. TG, FBG, FINS, HbA1c, HOMA-IR, HOMA-β, 25-OH-D3, and PTH are shown as the median ( and ). Male and season are shown as n (%). Symptomatic: polydipsia, polyuria, and loss of weight; BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; FFA, free fatty acids; Crea, creatinine; FBG, fasting blood glucose; FINS, fasting plasma insulin; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; Ca, blood calcium; P, blood phosphorus; 25-OH-D3, 25-hydroxyvitamin D3; PTH, parathyroid hormone.